Loading organizations...
§ Private Profile · Kingston, NY, USA
Biotechnology company developing targeted cancer therapies using computational drug discovery, focused on the apoptosis pathway.
BAKX Therapeutics was a Watertown, Massachusetts-based biotechnology company that developed targeted cancer therapies focused on the mitochondrial apoptosis pathway using computational drug discovery. The enterprise built an integrated platform combining biological experimentation and computer simulation to overcome treatment resistance, though it officially ceased operations on July 1, 2023, due to a challenging funding environment. Prior to its closure, the research firm raised $25 million in Series A financing co-led by institutional investors Droia Ventures and Novo Holdings. The business also secured an exclusive strategic collaboration agreement with global biopharmaceutical company Ipsen to develop and commercialize its lead leukemia and lymphoma therapy, BKX-001, in a deal structured with up to $837.5 million in potential milestone payments. BAKX Therapeutics was originally founded in 2020 by Sree Kant, Evripidis Gavathiotis, Yibing Shan, Richard Labaudinière, and Loren D. Walensky.
BAKX Therapeutics has raised $25.0M across 1 funding round.
BAKX Therapeutics has raised $25.0M in total across 1 funding round.
BAKX Therapeutics has raised $25.0M in total across 1 funding round.
BAKX Therapeutics's investors include Yibing Shan, Philippe Lopes-Fernandes, Sherpa Healthcare Partners.
BAKX Therapeutics has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 18, 2021 | $25M Series A | Yibing Shan | Philippe Lopes Fernandes, Sherpa Healthcare Partners | Announced |